Ayala Pharmaceuticals Inc (fka ADXS)

[Tupoofy]

IND submissions and IST trial initiations are money vacuums.
The only key outputs to focus on to see this stock bump up due to results for this coming 12 months are:
ADXS-PSA • MetastaticProstatePh1/2Combinationwithpembrolizumab-- Part B Monotherapy Combination Therapy Data (12-mo PFS and OS) Q1 2019
ADXS-NEO • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT NSCLC • Clinical data from initial cohort (safety, immune response) 1H 2019
ADXS-HOT Bladder • IND Submission 2019

And the PSA data released at poster session during ASCO 2018 was not objectively impressive.

We can always continue to pray Ken makes a deal though!